merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>  
<answer>Eli Lilly's vials are subject to more oversight than compounded drugs, which are subject to far less oversight and have unique risks.</answer>  

<question_number>2</question_number>  
<answer>LillyDirect allows patients to purchase Zepbound vials directly from Eli Lilly, bypassing telehealth companies that offer compounded medications.</answer>  

<question_number>3</question_number>  
<answer>The implicit risk is that compounded drugs are subject to far less oversight than traditionally approved medications, posing safety concerns.</answer>  

<question_number>4</question_number>  
<answer>Offering vials at a lower price could attract patients who cannot afford pens, potentially regaining customers from compounded tirzepatide.</answer>  

<question_number>5</question_number>  
<answer>The FDA's shortage list allows compounding pharmacies to produce alternative versions of tirzepatide, which Lilly is challenging legally.</answer>  

<question_number>6</question_number>  
<answer>Lilly's direct-to-consumer sales through LillyDirect reflect a trend of removing third-party supply chain entities to offer transparent pricing.</answer>  

<question_number>7</question_number>  
<answer>Medicare's current stance on not covering weight-loss medications could lead patients to seek cheaper alternatives like compounded drugs, which Eli Lilly's vials aim to address.</answer>  

<question_number>8</question_number>  
<answer>Eli Lilly's vials may be perceived as safer than compounded tirzepatide due to more oversight and FDA approval.</answer>  

<question_number>9</question_number>  
<answer>Tirzepatide is on the FDA's shortage list, allowing compounding pharmacies to legally produce alternative versions.</answer>  

<question_number>10</question_number>  
<answer>Dr. Timothy Mackey suggests that offering lower-priced vials is an indirect method to regain market share from compounding pharmacies.</answer>